Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
KIN's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KIN: No Debt )
KIN' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
KIN's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KIN: No Debt )
KIN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -6.66
KIN's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KIN: -6.66 )
KIN' s 10-Year ROE (%) Range
Min: -6.66   Max: -6.66
Current: -6.66

ROA (%) -6.43
KIN's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KIN: -6.43 )
KIN' s 10-Year ROA (%) Range
Min: -6.43   Max: -6.43
Current: -6.43

ROC (Joel Greenblatt) (%) -35158.33
KIN's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KIN: -35158.33 )
KIN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -35158.33   Max: -35158.33
Current: -35158.33

» KIN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

KIN Guru Trades in

Q4 2013

KIN Guru Trades in Q4 2013

Seth Klarman 2,900,000 sh (New)
» More
Q1 2014

KIN Guru Trades in Q1 2014

Steven Cohen 15,790 sh (New)
Seth Klarman 2,763,848 sh (-4.69%)
» More
Q2 2014

KIN Guru Trades in Q2 2014

Seth Klarman 2,763,848 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with KIN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Seth Klarman 2013-12-31 New Buy0.92%$11 - $12.37 $ 14.6122%2900000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Kindred Biosciences Inc

Seth Klarman Buys New Stock Kindred Biosciences, Cuts Stake in Enzon
Seth Klarman (Trades, Portfolio) of the Boston-based Baupost Group, which trades sparingly, has purchased a new stock: Kindred Biosciences (KIN), according to GuruFocus Real Time Picks. Read more...

Ratios

vs
industry
vs
history
P/B 3.90
KIN's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KIN: 3.90 )
KIN' s 10-Year P/B Range
Min: 0   Max: 5.6
Current: 3.9

0
5.6
EV-to-EBIT 6.10
KIN's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KIN: 6.10 )
KIN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 6.1

Current Ratio 23.24
KIN's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KIN: 23.24 )
KIN' s 10-Year Current Ratio Range
Min: 10.63   Max: 29.63
Current: 23.24

10.63
29.63
Quick Ratio 23.24
KIN's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KIN: 23.24 )
KIN' s 10-Year Quick Ratio Range
Min: 10.63   Max: 29.63
Current: 23.24

10.63
29.63

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.10
KIN's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KIN: 4.10 )
KIN' s 10-Year Price/Net Cash Range
Min: 0   Max: 0
Current: 4.1

Price/Net Current Asset Value 4.10
KIN's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KIN: 4.10 )
KIN' s 10-Year Price/Net Current Asset Value Range
Min: 0   Max: 0
Current: 4.1

Price/Tangible Book 4.10
KIN's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. KIN: 4.10 )
KIN' s 10-Year Price/Tangible Book Range
Min: 0   Max: 0
Current: 4.1

Business Description

Industry: »
Compare: » details
» More Articles for KIN

Headlines

Articles On GuruFocus.com
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
Seth Klarman Buys New Stock Kindred Biosciences, Cut Stake in Enzon Jan 10 2014 

More From Other Websites
Kindred Biosciences Announces Second Quarter 2014 Financial Results Aug 14 2014
CFO Moves: Kindred Biosciences, ITC Holdings Aug 13 2014
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition Aug 13 2014
Kindred Biosciences Announces Second Quarter 2014 Financial Results Aug 13 2014
KindredBio Schedules Release of 2014 Second Quarter Financial Results and Provides Timeline for... Aug 11 2014
Cannabis Therapy Expands into Animal Health Marketplace Aug 06 2014
KindredBio Schedules Release of 2014 Second Quarter Financial Results and Provides Timeline for... Aug 06 2014
Pet Meds: Tested on Humans, Safe for Animals Jul 21 2014
3 Health Care Stocks Primed For Big Moves Jul 14 2014
Kindred Bio to Host Investor Breakfast on June 13 in New York City Jun 11 2014
Kindred Biosciences initiated with a Buy at Craig-Hallum May 23 2014
Kindred Bio to Present at Craig-Hallum, Stifel, and Jefferies Conferences May 21 2014
KINDRED BIOSCIENCES, INC. Financials May 21 2014
Seth Klarman's Baupost: Investment Changes During The First Quarter May 19 2014
KINDRED BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report May 14 2014
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition May 12 2014
Kindred Biosciences reports Q1 EPS (38c), consensus (19c) May 12 2014
Kindred Biosciences Announces First Quarter 2014 Financial Results and Completion of Enrollment in... May 12 2014
Kindred Bio to Announce First Quarter 2014 Financial Results on Monday, May 12th May 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide